NYSE
$160.83▲ 1.35%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $17.94BShares out 1.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 10.7Regular26.10.08 03:56SCHEDULE 13G/AOwnership#●●●
REVVITY, INC.
T. Rowe Price Associates has filed a Schedule 13G/A amendment regarding its beneficial ownership stake in Revvity, Inc. This filing represents a routine update to the firm's existing position and does not indicate any immediate changes to the company's management or corporate structure.…more
$160.83+1.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 05:054Ownership
REVVITY, INC.
Insider Anita Gonzales of Revvity, Inc. reported a change in beneficial ownership of securities effective October 1, 2026. This filing serves as a standard Form 4 disclosure regarding changes in executive stock holdings.…more
$160.83+1.35%vs prev closeView filingShare - 10.1Regular26.10.01 23:48144Ownership
REVVITY, INC.
Anita Gonzales, an insider at Revvity, Inc., has filed a Form 144 to report a proposed sale of company securities. This is a standard filing disclosing an insider's plan to dispose of shares.…more
$160.83+1.35%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.24Pre-market26.09.24 21:03#●●●#●●●
Revvity Launches GSP T1D 3plex Screening Kit
Revvity has introduced the GSP T1D 3plex kit, an automated solution designed to identify children at risk for type 1 diabetes before symptoms manifest. The product has received CE-IVDR certification to support population-wide screening programs.…more
$160.83+1.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.9Regular26.09.09 22:35
●●●●●●●● ●●●●● ●●●●●●
Revvity has agreed to acquire France-based Human Cell Design to enhance its research capabilities in diabetes and obesity treatments. The deal aims to integrate the target's cell models with Revvity's existing drug discovery platform, though financial terms remain undisclosed.…more
$160.83+1.35%vs prev closeShareBenzinga - 9.9Pre-market26.09.09 19:09
●●●●●●●● ●●●●● ●●●●●●
Revvity has announced the acquisition of Human Cell Design to bolster its capabilities in diabetes and obesity research. The deal integrates specialized human pancreatic beta cell models into Revvity's life sciences portfolio to enhance drug discovery and preclinical research.…more
$160.83+1.35%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report